Free Trial
NYSE:HIMS

Hims & Hers Health (HIMS) Stock Price, News & Analysis

Hims & Hers Health logo
$34.34 -1.61 (-4.48%)
Closing price 03/10/2025 03:59 PM Eastern
Extended Trading
$33.15 -1.19 (-3.47%)
As of 03/10/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Hims & Hers Health Stock (NYSE:HIMS)

Key Stats

Today's Range
$33.33
$37.15
50-Day Range
$24.18
$68.87
52-Week Range
$11.20
$72.98
Volume
29.21 million shs
Average Volume
13.24 million shs
Market Capitalization
$7.63 billion
P/E Ratio
78.04
Dividend Yield
N/A
Price Target
$37.23
Consensus Rating
Hold

Company Overview

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Remove Ads

Hims & Hers Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

HIMS MarketRank™: 

Hims & Hers Health scored higher than 62% of companies evaluated by MarketBeat, and ranked 370th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 6 buy ratings, 7 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Hims & Hers Health has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Hims & Hers Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Hims & Hers Health are expected to grow by 79.31% in the coming year, from $0.29 to $0.52 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hims & Hers Health is 78.04, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.50.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hims & Hers Health is 78.04, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.90.

  • Price to Book Value per Share Ratio

    Hims & Hers Health has a P/B Ratio of 21.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Hims & Hers Health's valuation and earnings.
  • Percentage of Shares Shorted

    25.41% of the float of Hims & Hers Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently decreased by 20.77%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Hims & Hers Health does not currently pay a dividend.

  • Dividend Growth

    Hims & Hers Health does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    25.41% of the float of Hims & Hers Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently decreased by 20.77%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Hims & Hers Health has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 44 news articles for Hims & Hers Health this week, compared to 19 articles on an average week.
  • Search Interest

    283 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 26% compared to the previous 30 days.
  • MarketBeat Follows

    78 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 179% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,892,724.00 in company stock.

  • Percentage Held by Insiders

    17.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Hims & Hers Health's insider trading history.
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

HIMS Stock News Headlines

Novo Nordisk sogn
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors (HIMS)
Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.
Financial markets news icon
MarketBeat Week in Review – 03/03 - 03/07 (HIMS)
Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continue
DOGE officially begins retirement transformation
Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retirement" process . This fired the starting gun on the biggest economic transformation in American history.
Clover Health computer and stethoscope
Missed the Hims & Hers Rally? Clover Health Could Be Next
After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space.
Technical price graph and indicator, red and green candlestick chart on blue theme screen, market volatility, up and down trend. Stock trading, crypto currency background. — Photo
Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now (HIMS)
See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes.
3 Cold Stocks That Can Bounce Back This Week
Hims & Hers: AI-Powered Healthcare Disruption
See More Headlines

HIMS Stock Analysis - Frequently Asked Questions

Hims & Hers Health's stock was trading at $24.18 on January 1st, 2025. Since then, HIMS stock has increased by 42.0% and is now trading at $34.3380.
View the best growth stocks for 2025 here
.

Hims & Hers Health, Inc. (NYSE:HIMS) posted its quarterly earnings results on Monday, February, 24th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The business earned $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a trailing twelve-month return on equity of 10.97%.

Top institutional shareholders of Hims & Hers Health include Vanguard Group Inc. (9.27%), Farallon Capital Management LLC (3.83%), Renaissance Technologies LLC (3.18%) and Arrowstreet Capital Limited Partnership (2.89%). Insiders that own company stock include Melissa Baird, David B Wells, Alex Bard, Patrick Harrison Carroll, Michael Chi, Soleil Boughton, Jules A Maltz, Christopher D Payne, Oluyemi Okupe, Andrew Dudum, Christiane Pendarvis, Irene Becklund, Anja Manuel and Lynne Chou O'keefe.
View institutional ownership trends
.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
2/24/2025
Today
3/11/2025
Next Earnings (Estimated)
5/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Offices & clinics of medical doctors
Sub-Industry
Healthcare
Current Symbol
NYSE:HIMS
Fax
N/A
Employees
1,046
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.23
High Stock Price Target
$68.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+8.4%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
15 Analysts

Profitability

Trailing P/E Ratio
78.04
Forward P/E Ratio
118.41
P/E Growth
N/A
Net Income
$-23,550,000.00
Pretax Margin
4.16%

Debt

Sales & Book Value

Annual Sales
$1.48 billion
Price / Cash Flow
N/A
Book Value
$1.61 per share
Price / Book
21.33

Miscellaneous

Free Float
179,786,000
Market Cap
$7.63 billion
Optionable
Optionable
Beta
1.37
10 Best Stocks to Own in 2025 Cover

Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NYSE:HIMS) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners